<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区
          您現(xiàn)在的位置: > Language Tips > Audio & Video > Special Speed News  
           





            Once-daily pill could simplify HIV treatment
          [ 2006-02-06 15:57 ]


          I’m Steve Ember with the VOA Special English Health Report.


          Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
          Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

          But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

          Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

          They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

          Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

          In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

          Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

          GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

          The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

          They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

          There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

          Experts say more than forty million people around the world are living with H.I.V.

          This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

          Vocabulary

           

           

           
           
           




          主站蜘蛛池模板: 麻花传媒免费网站在线观看| 精品国产欧美一区二区三区在线| 国产一区二区三区不卡自拍| 日本一区三区高清视频| 福利一区二区三区视频在线| 丰满人妻一区二区三区视频| 亚洲av永久无码天堂影院| 粉嫩在线一区二区三区视频| 亚洲熟妇色xxxxx亚洲| 内射一区二区三区四区| 午夜无码无遮挡在线视频| 久久精品国产亚洲av高清蜜臀| 日韩中文字幕人妻一区| 国产成人av三级在线观看| 亚洲岛国av一区二区| 欧美在线一区二区三区精品| 久久人人97超碰人人澡爱香蕉| 亚洲色大成永久WW网站| 日本一区二区三区精品国产| 国产不卡一区二区在线| 男女肉粗暴进入120秒视频| 少妇人妻偷人精品一区二| 亚洲国产欧美在线人成| 成人av天堂网在线观看| 亚洲精品久综合蜜| 熟女少妇精品一区二区| 精品国产性色av网站| 国产裸舞福利在线视频合集| 日本一区不卡高清更新二区| 好吊色妇女免费视频免费| 国产久久热这里只有精品| 国精产品自偷自偷ym使用方法| 起碰免费公开97在线视频| 免费99精品国产人妻自在现线| 91麻豆国产精品91久久久| 少妇粗大进出白浆嘿嘿视频| 午夜国产精品视频免费看电影| 久久人人爽人人爽人人av| 成人av在线一区二区三区| 国产综合久久久久久鬼色| 国产又爽又黄又爽又刺激|